Increasing Cases of Influenza in the U.S. Is Driving the Growth of the Market

 

U.S. Influenza Vaccines Market

U.S. Influenza Vaccines Market, by Vaccine Type (Trivalent Vaccines, Quadrivalent Vaccines), by Virus Type (Influenza Virus Type A, Influenza Virus Type B), by Age Group (Pediatrics, Adults) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030.

Market Overview:

Influenza, commonly known as the flu, is a severely contagious respiratory disease caused by the influenza virus. It can cause mild to severe illness, and in some cases, can even be fatal. The symptoms of influenza can include fatigue, chills, headache, body aches, stuffy or runny nose, sore throat, cough and fever. Influenza is typically spread through respiratory droplets. The best way to prevent influenza is by getting an annual flu vaccine and practicing good hygiene, such as washing hands frequently and covering coughs and sneezes.

Influenza can be a serious and potentially life-threatening illness, especially in certain high-risk groups such as young children, elderly adults, pregnant women, and individuals with weakened immune systems or underlying health conditions. Complications of influenza can include pneumonia, bronchitis, sinus infections, ear infections, and worsening of chronic medical conditions such as asthma and heart disease. In severe cases, influenza can lead to hospitalization and even death.

Competitive Landscape:

Major players operating in the U.S. influenza vaccines market include EMERGENT, Novavax, INOVIO Pharmaceuticals, Moderna, Inc., Protein Sciences Corporation, Merck & Co., Inc., Novartis AG, AstraZeneca, Pfizer Inc., Sanofi, GSK plc., and Seqirus USA Inc.

Key Market Drivers:

The major drivers of the U.S. influenza vaccines market include the increasing incidence of influenza infections, the growing awareness about the importance of vaccination in preventing seasonal flu, and the rise in government initiatives to promote immunization programs. For instance, according to Forbes, in 2021, there were around 9 million cases of influenza in the United States.

The emergence of new strains of the influenza virus is also estimated to enhance the growth of the U.S. influenza vaccines market. Additionally, the growing elderly population, which is more susceptible to influenza, is expected to drive the demand for influenza vaccines in the U.S. Covid-19 Impact Analysis:

The COVID-19 pandemic has had a significant impact on the U.S. influenza vaccines market. Due to the COVID-19 pandemic, there has been a significant increase in the demand for influenza vaccines as people become more aware of the importance of vaccination in preventing infectious diseases. The COVID-19 pandemic has also led to an increase in the use of telemedicine and virtual consultations, which has facilitated the distribution of influenza vaccines.

Key Takeaways:

·         High awareness related to vaccination U.S. is expected to dominate the growth of the U.S. influenza vaccines market. For instance, according to the Centers for Disease Control and Prevention, there were around 5000 deaths in the U.S. due to influenza.

·         The increasing prevalence of the geriatric population in the U.S. is estimated to augment the growth of the U.S. influenza vaccines market. For instance, according to the U.S. Census Bureau, there are over 56 million elderly individuals in the U.S. (65 years or more).